Literature DB >> 15547080

Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis.

S Van Doornum1, G McColl, I P Wicks.   

Abstract

BACKGROUND: Chronic systemic inflammation may contribute to accelerated atherosclerosis and increased arterial stiffness in patients with rheumatoid arthritis (RA). In addition to lowering cholesterol, statins have immunomodulatory effects which may be especially beneficial in patients with RA who have systemic immune activation.
OBJECTIVE: To investigate the effect of atorvastatin on the augmentation index (AIx: a measure of arterial stiffness) and systemic inflammation in RA.
METHODS: 29 patients with RA (mean (SD) age 55 (13) years) with moderately active disease of long duration were studied. AIx, lipid levels, serum inflammatory markers, and disease activity score were measured before and after 12 weeks of atorvastatin 20 mg daily.
RESULTS: AIx improved significantly from 34.1 (11.6)% to 29.9 (11)% (p = 0.0002), with the greatest improvements in AIx occurring in those subjects with the highest disease activity scores (r = -0.5, p = 0.007). Total and LDL cholesterol were reduced from 5.5 (0.9) to 3.9 (0.7) mmol/l and 3.3 (0.8) to 1.9 (0.6) mmol/l, respectively (p = 0.0001). Serum inflammatory markers remained unchanged during the study.
CONCLUSIONS: Atorvastatin significantly reduced arterial stiffness in patients with RA. The greatest improvements were seen in patients with more active disease, suggesting that, in addition to the beneficial effects of cholesterol reduction, immune modulation may contribute to the cardioprotective effect of statins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547080      PMCID: PMC1754856          DOI: 10.1136/ard.2003.018333

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  58 in total

1.  A tale of two diseases: atherosclerosis and rheumatoid arthritis.

Authors:  V Pasceri; E T Yeh
Journal:  Circulation       Date:  1999-11-23       Impact factor: 29.690

2.  A comparison between systolic and diastolic pulse contour analysis in the evaluation of arterial stiffness.

Authors:  E R Rietzschel; E Boeykens; M L De Buyzere; D A Duprez; D L Clement
Journal:  Hypertension       Date:  2001-06       Impact factor: 10.190

3.  Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients.

Authors:  S Laurent; P Boutouyrie; R Asmar; I Gautier; B Laloux; L Guize; P Ducimetiere; A Benetos
Journal:  Hypertension       Date:  2001-05       Impact factor: 10.190

4.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

5.  Association between arterial stiffness and atherosclerosis: the Rotterdam Study.

Authors:  N M van Popele; D E Grobbee; M L Bots; R Asmar; J Topouchian; R S Reneman; A P Hoeks; D A van der Kuip ; A Hofman; J C Witteman
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

6.  Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis.

Authors:  G E McVeigh; P B Allen; D R Morgan; C G Hanratty; B Silke
Journal:  Clin Sci (Lond)       Date:  2001-04       Impact factor: 6.124

7.  Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells.

Authors:  U Ikeda; M Shimpo; R Ohki; H Inaba; M Takahashi; K Yamamoto; K Shimada
Journal:  Hypertension       Date:  2000-09       Impact factor: 10.190

8.  Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits.

Authors:  Y Fukumoto; P Libby; E Rabkin; C C Hill; M Enomoto; Y Hirouchi; M Shiomi; M Aikawa
Journal:  Circulation       Date:  2001-02-20       Impact factor: 29.690

9.  HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins.

Authors:  Z Yang; T Kozai; B van der Loo; H Viswambharan; M Lachat; M I Turina; T Malinski; T F Lüscher; B van de Loo
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

10.  3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1).

Authors:  U Laufs; D Marra; K Node; J K Liao
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

View more
  41 in total

1.  Effect of Atorvastatin on the Disease Activity and Severity of Rheumatoid Arthritis: Double-Blind Randomized Controlled Trial.

Authors:  Karim Mowla; Elham Rajai; Ali Ghorbani; Mehrdad Dargahi-Malamir; Mohammad Bahadoram; Shooka Mohammadi
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats.

Authors:  Venkatesan Saratha; Sorimuthu Pillai Subramanian
Journal:  Inflammopharmacology       Date:  2011-10-16       Impact factor: 4.473

3.  Preventing Heart Failure in Inflammatory and Immune Disorders.

Authors:  Maya Serhal; Chris T Longenecker
Journal:  Curr Cardiovasc Risk Rep       Date:  2014-06

4.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

5.  Primary care providers' awareness, knowledge, and practice with regard to cardiovascular risk in patients with rheumatoid arthritis : PCPs' awareness, knowledge, and practice with regard to CV risks in patients with RA.

Authors:  Stella Pak
Journal:  Clin Rheumatol       Date:  2019-12-24       Impact factor: 2.980

Review 6.  Pharmacological modulation of arterial stiffness.

Authors:  Pierre Boutouyrie; Patrick Lacolley; Marie Briet; Véronique Regnault; Alice Stanton; Stéphane Laurent; Azra Mahmud
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

7.  Physical activity and self-reported cardiovascular comorbidities in persons with multiple sclerosis: evidence from a cross-sectional analysis.

Authors:  Robert W Motl; Bo Fernhall; Edward McAuley; Gary Cutter
Journal:  Neuroepidemiology       Date:  2011-05-20       Impact factor: 3.282

8.  Relationship between arterial dysfunction and extra-articular features in patients with rheumatoid arthritis.

Authors:  Michael A Crilly; Vinod Kumar; Hazel J Clark; David J Williams; Alan G Macdonald
Journal:  Rheumatol Int       Date:  2011-03-27       Impact factor: 2.631

Review 9.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Cynthia S Crowson; Katherine P Liao; John M Davis; Daniel H Solomon; Eric L Matteson; Keith L Knutson; Mark A Hlatky; Sherine E Gabriel
Journal:  Am Heart J       Date:  2013-08-29       Impact factor: 4.749

10.  Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study.

Authors:  Gabriel Chodick; Howard Amital; Yoav Shalem; Ehud Kokia; Anthony D Heymann; Avi Porath; Varda Shalev
Journal:  PLoS Med       Date:  2010-09-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.